ArticleBlood cancer journal2021
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.American journal of hematology · 2026Article
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Pathogenesis and kidney prognosis of renal amyloidosis.Cellular and molecular life sciences : CMLS · 2026Review
- Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.Circulation. Heart failure · 2026Article
- Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis.Annals of medicine · 2025Article
- Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines · 2025Article
- Article
- Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.JACC. CardioOncology · 2025Article
- Recent developments in systemic light-chain amyloidosis prognosis and treatment.Future cardiology · 2025Review
- Between Charybdis and Scylla-an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series.Therapeutic advances in hematology · 2025Article
- Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.Frontiers in immunology · 2025Review
- Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation.Annals of medicine · 2024Observational
- Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.BMC cancer · 2024Article
- Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.Clinical and experimental medicine · 2024Article
- Autologous stem cell transplantation in AL amyloidosis: Muddy waters.Blood reviews · 2024Review
- Circulating tumor cells help differentiate benign ovarian lesions from cancer before surgery: A literature review and proof of concept study using flow cytometry with fluorescence imaging.Oncology letters · 2024Article
- Review
- Relapsed systemic light chain amyloidosis - in search of a higher bar.Bone marrow transplantation · 2024Article
- Successful autologous stem cell transplantation for light chain proximal tubulopathy with severe kidney injury.Clinical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) and restore organ function. However, even complete hematologic response (CR), defined as negative serum and urine immunofixation and normalized free LC ratio, does not always translate into organ response. Next-generation flow (NGF) cytometry is used to detect minimal residual disease (MRD) in multiple myeloma. We evaluated MRD by NGF in 92 AL amyloidosis patients in CR. Fifty-four percent had persistent MRD (median 0.03% abnormal plasma cells). There were no differences in baseline clinical variables in patients with or without detectable MRD. Undetectable MRD was associated with higher rates of renal (90% vs 62%, p = 0.006) and cardiac response (95% vs 75%, p = 0.023). Hematologic progression was more frequent in MRD positive (0 vs 25% at 1 year, p = 0.001). Altogether, NGF can detect MRD in approximately half the AL amyloidosis patients in CR, and persistent MRD can explain persistent organ dysfunction. Thus, this study supports testing MRD in CR patients, especially if not accompanied by organ response. In case MRD persists, further treatment could be considered, carefully balancing residual organ damage, patient frailty, and possible toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.